A Randomized, Open Label, Single-Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276 in Healthy Male Volunteers

Trial Profile

A Randomized, Open Label, Single-Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276 in Healthy Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2013

At a glance

  • Drugs Olmesartan medoxomil/rosuvastatin (Primary) ; Olmesartan medoxomil; Rosuvastatin
  • Indications Atherosclerosis; Hypercholesterolaemia; Hyperlipidaemia; Hypertension; Hypertriglyceridaemia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 26 Jun 2013 Primary endpoint 'Peak-drug-concentration' has been met according to results published in Clinical Therapeutics.
    • 26 Jun 2013 Primary endpoint 'Area-under-the-drug-concentration-time-curve' has been met according to results published in Clinical Therapeutics.
    • 26 Jun 2013 Results published in Clinical Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top